Lakewood-Amedex Biotherapeutics (LABT) investor relations material

Executive summary

• Clinical-stage biopharma focused on novel antimicrobials for infectious diseases, especially antibiotic-resistant strains like MRSA and VRE, with 68 issued and 36 pending patents as of April 2026.

• Lead product Nu-3 completed first human trial for diabetic foot ulcers; Phase 2 studies planned, with additional pipeline compounds under development.

• Net loss of $0.9 million for Q1 2026, with accumulated deficit of $54.3 million as of March 31, 2026.

• Completed $7.5 million Series C Preferred Stock financing in April 2026, improving liquidity but additional capital will be needed beyond Q4 2026.

Financial highlights

• Q1 2026 net loss: $923,291, up from $539,617 in Q1 2025.

• Operating expenses rose to $886,750 in Q1 2026 from $542,609 in Q1 2025, driven by higher R&D and G&A costs.

• Cash and cash equivalents at March 31, 2026: $11,709, down from $236,400 at year-end 2025.

• Net cash used in operating activities for Q1 2026: $349,691; net cash provided by financing activities: $125,000.

• Accumulated deficit: $54.3 million as of March 31, 2026.

Outlook and guidance

• Proceeds from Series C financing and debt conversions expected to fund operations through Q4 2026.

• Additional capital will be required to fund operations and execute business plan beyond 2026; management cannot assure such funding will be available.

• Planned Phase 2 clinical trials for Nu-3 and continued advancement of early-stage pipeline.